Table 3.
Changes in flu vaccination coverage between 2017–18, 2018–19 and 2019–2020 seasons
| Patient characteristics | 2017–2018 | 2018–2019 | 2019–2020 | p |
|---|---|---|---|---|
| Total (n) | 58.3% (43) | 69.2% (63) | 75.5% (69) | <.01* |
| Over 65 years old | 75.7% | 88.6% | 88.9% | .08 |
| Males | 54.6% | 75.0% | 93.8% | .04* |
| Females | 59.0% | 81.0% | 72.0% | .12 |
| Comorbidities | 60.4% | 75.0% | 76.9% | .05* |
| Interstitial Lung Disease | 58.7% | 77.4% | 76.8% | .07 |
| Cardiovascular | 76.9% | 75.5% | 77.6% | .99 |
| Ongoing therapy | 34.9% | 83.8% | 83.8% | <.01* |
| Methotrexate | 60.0% | 87.5% | 87.5% | .46 |
| Mycophenolate mofetil | 73.3% | 84.0% | 83.3% | .67 |
Statistical significance examined with Fisher’s exact test (the result is significant if p < .05) and the chi-square test, applying the Yates correction when necessary; * statistical significance.